Embrace a future-orientated approach with an invaluable resource: our comprehensive Viral Vector Manufacturing Market report. This in-depth analysis offers essential insights into a rapidly growing market, spotlighting potential opportunities and exploring current trends.
The significance of the field is intricately connected to our current global focus in healthcare. Vaccination development and viral disease treatment are at the forefront of medical research, underpinning a substantial growth within the viral vector manufacturing market. Medical trailblazers like AstraZeneca and Janssen Biotech illustrate the potential strides in viral vectored vaccine manufacturing, underscoring the necessity for this crucial resource.
The prevalence of genetic disorders, cancer, and infectious diseases is accelerating the necessity for new viral vector products. Substantial public and private sector initiatives are also driving the evolution of this field. Actions such as government funding, regulatory alterations, and targeted investments by key market players continually propel forward the proliferation of viral vector manufacturing.
In the midst of significant growth, pause to explore the expansive opportunities available within the viral vector manufacturing market, and journey into a future of healthcare transformation using our detailed analysis as your guide.
The COVID-19 pandemic has underlined the importance of vaccine development for the global population, and it has had a positive impact on the growth of the viral vector manufacturing market. According to the World Health Organization (WHO) Global COVID-19 Vaccination - Strategic Vision for 2022, there are at least 17 vaccines in use. As of September 6, 2021, 5.4 billion doses were administered, and another 300 and more vaccine candidates were in clinical and preclinical development. Two viral vector vaccines have been authorized for emergency use in many countries for the COVID-19 vaccine as of January 7, 2022, according to the Viral Vector Vaccines segment published by the Infectious Diseases Society of America. For instance, in April 2020, AstraZeneca and Oxford University announced their partnership to develop a viral vectored vaccine utilizing a modified replication-deficient chimp adenovirus vector, ChAdOx1. Also, Janssen Biotech (Johnson & Johnson) has developed a viral vectored vaccine utilizing a replication-incompetent human adenovirus vector and received approval from Food and Drug Administration (FDA) in February 2021. the importance of viral vector manufacturing is increasing owing to the increasing research and developments occurring in current times.
The market is driven by the increasing prevalence of the genetics disorder, cancer and infectioud diseases, increasing number of clinical studies and availability of funding for gene therapy development, potential applications in novel drug delivery approaches. The increase in several genetic disorders and infectious diseases is also affecting the growth of viral vector production. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) Statistics, in 2021, 27.5 million people were living with human immunodeficiency virus (HIV) globally at the end of 2020, and 1.5 million (1.0 million - 2.0 million) people became newly infected with HIV. Among the total HIV infected, 87% of people living with HIV knew that their HIV status was accessing antiretroviral therapy, and 90% of people on treatment were virally suppressed. This prevalence of numerous infectious and viral diseases is motivating the major companies to focus on viral vector product development and manufacturing.
Additionally, as the recombinant viral vectors are highly effective carriers of sequences encoding virus-disabling sequences, the appropriate and exact viral vectors usually need to be selected and adapted for application in the treatment of specific viral infections. Currently, there have been significant public and private sector initiatives are being taken for the development of viral vector vaccines, leading the key players to invest in capacity expansion for manufacturing activities. For example, in November 2020, a global contract development and manufacturing organization, Vibalogics announced its plans to invest USD 150 million to build a 110,000 square-foot facility near Boston in the United States. The facility will be used to produce clinical and commercial-stage oncolytic viruses and viral vectors. These related development activities by major players are also expected to boost the market’s growth.
Government initiatives such as direct funding towards viral vector manufacture, which is increasing awareness, while the regulatory environment is getting streamlined via changes, such as prompt approval processes, are driving the studied market’s growth. These aforementioned factors can propel the market for viral vector manufacturing and are expected to grow in the future. However, the high cost of gene therapies and challenges in viral vector manufacturing capacity can impact market growth negatively.
Viral Vector Manufacturing Market Trends
Cancer Sub-segment is Expected to Grow Faster in the Disease SegmentThe upsurge in the global incidence of cancer and modern healthcare facilities are acting as major drivers for the growth of the market studied. According to GLOBOCAN 2020, globally, there were 1,92,92,789 new cancer cases in 2020, and it is projected to increase to 2,88,87,940 cases by 2040. The upsurge in the global incidence of cancer and modern healthcare facilities is acting as a major driver for the growth of the market studied. In 2021, there are numerous Phase I, Phase II, Phase III, and Phase IV clinical trials related to viral vectors for the treatment of various types of cancers such as brain, skin, liver, colon, breast, and kidney. These trials are being conducted in various academic centers and biotechnology companies. For instance, as of March 29, 2021, more than 90 ongoing interventional clinical trials related to gene therapy across different phases of development for cancer were there globally, as mentioned in the National Clinical Trial (NCT) Registry.
In the field of oncology, viral vector-based gene therapy has demonstrated steady progress. A variety of viral vectors have been engineered for both therapeutic and preventive applications in cancers. Many gene therapy strategies have been developed to treat a wide range of cancers, including suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines. According to the study titled ' Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age' published in the Radiology and Oncology in March 2022, Numerous opportunities exist for using viral vectors in cancer therapy. Due to their improved ability to transduce human cells, viral vectors are a desirable drug delivery option. Over a thousand clinical trials using viral vectors are being conducted worldwide to treat cancer in 2021. Thus, owing to the increase in global cancer incidence, the market is expected to see growth.
The increasing research and development activities for the development of viral vector vaccines or therapies are increasing the opportunity for novel products developments. For Instance, in September 2021, Building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2, researchers from the University of Oxford and the Ludwig Institute for Cancer Research are creating a vaccine to treat cancer. a viral vector cancer vaccine reduces tumour size and improves survival rates in mouse models by generating efficient anti-tumor immune responses when combined with immunotherapy. it is expected that, a first-in-human clinical trial of the therapeutic cancer vaccine will begin in patients with non-small cell lung cancer in the coming year. Thus, growing research and development activity on the viral vector bases cancer manufacturing vaccines
The surge in demand for the development of effective therapeutics for cancer management, the presence of a prompt approval process, and the prospects of novel drugs for significant product developments are the primary reasons responsible for significant research and development investments in the field of cancer therapeutics that are based on viral vectors. This, in turn, affects the growth of the cancer segment positively, and the cancer segment is hence expected to boost the market’s growth.
North America Dominates the Market, and the Region is Expected to Follow the Same Trend in the FutureNorth America currently dominates the market for viral vector manufacturing and is expected to continue its stronghold for a few more years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage. The significant incentives on offer through the Orphan Drugs Act (the United States) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable venture.
Many companies have been expanding their facilities and investing a significant amount of capital in the region. For example, in April 2020, Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility. The projected expansion was expected to double the company’s gene therapy manufacturing capacity. Novel viral vector development has advanced significantly, and several researchers are concentrating on replacing pathogenic genes with therapeutic DNA. In modern gene therapy clinical trials, non-pathogenic, replication-defective, and human-friendly viral vectors are frequently used. These developments could have a positive effect on market growth as more research on viral vectors is anticipated. In October 2021, Catalent has invested USD 230 million to increase the production of viral vectors at its gene therapy campus in Harmans, Maryland.
The United States holds the largest market share in the North American region owing to various factors like the high adoption rate of new therapies and the high incidence rate of cancer. Accordinng to the National cancer Institutes in September 2020, in the United States, there will likely be 1,806,590 new cancer diagnoses in 2020. A projected 43% of all cancers diagnosed in men in 2020 are colorectal, lung, and prostate cancers. Breast, lung, and colorectal cancers are the three most prevalent cancers in women, and in 2020, they will likely account for half of all new cancer diagnoses in female patients. The increasing prevalence of genetic and other chronic disorders, an aging population, growing demand for targeted and personalized medicine, and favorable government initiatives are the factors responsible for future market growth in the United States.
Viral Vector Manufacturing Market Competitor AnalysisThe viral vector manufacturing market is moderately competitive and has several key players. Owing to the growing demand for novel therapeutics to deal with life-threatening diseases, such as cancer, various smaller companies are also entering the market and holding a significant market share. Some of the key market players are Cognate BioServices Inc. (Cobra Biologics), Finvector, Fujifilm Holdings, Corporation (Fujifilm Diosynth Biotechnologies), Kaneka Corporation (Eurogentec), Merck KGaA, Uniqure NV, Oxford BioMedica PLC, Johnson & Johnson (Janssen Global Services LLC), AstraZeneca, Vibalogics, Danaher (Cytiva), Sanofi SA, F. Hoffmann-La Roche Ltd (Spark Therapeutics), Lonza, and Thermo Fisher Scientific Inc.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
4.2.2 Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development
4.2.3 Potential Applications in Novel Drug Delivery Approaches
4.3 Market Restraints
4.3.1 High Cost of Gene Therapies
4.3.2 Challenges in Viral Vector Manufacturing Capacity
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Adenoviral Vectors
5.1.2 Adeno-associated Viral Vectors
5.1.3 Lentiviral Vectors
5.1.4 Retroviral Vectors
5.1.5 Other Types
5.2 By Disease
5.2.2 Genetic Disorders
5.2.3 Infectious Diseases
5.2.4 Other Diseases
5.3 By Application
5.3.1 Gene Therapy
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.4.5 South America
184.108.40.206 Rest of South America
6.1.1 Charles River Laboratories (Cobra Biologics)
6.1.3 Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
6.1.4 Kaneka Eurogentec SA
6.1.5 Merck KGaA
6.1.6 uniQure NV
6.1.7 Oxford Biomedica PLC
6.1.8 Johnson & Johnson (Janssen Global Services LLC)
6.1.11 Danaher (Cytiva)
6.1.13 F. Hoffmann-La Roche Ltd (Spark Therapeutics)
6.1.15 Thermo Fisher Scientific Inc.
A selection of companies mentioned in this report includes:
- Charles River Laboratories (Cobra Biologics)
- Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
- Kaneka Eurogentec SA
- Merck KGaA
- uniQure NV
- Oxford Biomedica PLC
- Johnson & Johnson (Janssen Global Services LLC)
- Danaher (Cytiva)
- F. Hoffmann-La Roche Ltd (Spark Therapeutics)
- Thermo Fisher Scientific Inc.